Thelansis

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China ). Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview Metastatic castration-resistant prostate cancer (mCRPC) is an advanced, lethal malignancy defined by disease progression despite castrate levels of serum testosterone, driven by androgen receptor amplification, splice variants, or autonomous intra-tumoral steroidogenesis. ...

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook ...

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy and TPP Insights Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for ke...

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Access and Reimbursement Insights Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview Metastatic Castration-Resistant Prostate Cancer (mCRPC) denotes a high-burden malignancy in which lymphoid neoplasms either recur following an initial remission (relapsed) or do not respond adequately to conventional first-line therapies (refractory). Characterized by aggressive biological behavior, therapeutic resistance, and diminished survi...

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy and TPP Insights Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview Metastatic castration‑resistant prostate cancer is an advanced stage of prostate cancer in which the disease progresses despite androgen deprivation therapy. It is characterized by continued tumor growth and spread to distant sites, most commonly the bones and lymph nodes, even in the setting of low testosterone levels. Patients often experience pain, fatigue, urinary symptoms, and skeletal complications, which contribute to significant morbidity and reduced qu...

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Access and Reimbursement Insights Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated ...

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy and TPP Insights Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity...

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for s...

  Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview Prostate cancer (PCa) ranks among the most prevalent malignancies worldwide. Typically, men newly diagnosed with PCa exhibit localized disease and commonly undergo radical prostatectomy and radiological therapy, followed by androgen deprivation therapy (ADT). Within a decade,...

 Metastatic Castration-Resistant Prostate Cancer (mCRPC), characterized by its lengthy disease trajectory and diverse clinical outcomes among individual patients, predominantly affects men aged 45 to 60. Risk factors associated with this cancer encompass familial predisposition, ethnicity, age, obesity, and various environmental influences, with familial inheritance being a significant genetic risk factor. The majority of newly diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) cases initially present with localized disease, typically managed through radical prostatectomy and radiation therapy, followed by androgen deprivation therapy (ADT). However, within a decade, a variable percentage of patients progress to castration-resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) (CRPC). Among them, those with metastatic castration-resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MCRPC) face a particularly grim prognosis, with median surviva...

  Prostate cancer (PCa) is one of the most prevalent malignancies globally. Most men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the cancer grade, a variable percentage of these patients experience castration-resistant prostate cancer (CRPC) progression within ten years. Metastatic castration-resistant prostate cancer (MCRPC) patients remain incurable, with a relatively poor prognosis. For men with CRPC, the median survival ranges from 9 to 30 months, and for those with MCRPC, this survival is reduced to 9–13 months. Currently, cytotoxic chemotherapy agents, AR blocking agents, immunotherapies, and radiopharmaceuticals represent effective therapeutic strategies for MCRPC treatment. Taxane chemotherapy (docetaxel and cabazitaxel) is the standard for MCRPC treatment.   Prostate cancer (PCa) incidence ranges from 95 to 112 cases per 100,000 popu...